Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 million equity investment by Gilead in Arcus common stock at $21.00 per share. This strategic investment and collaboration amendment are set to accelerate the growth of their joint development programs […]